BRIEF

on Immunic AG

Immunic to Join March Conferences to Present Research

Immunic, Inc., a biotechnology firm focused on treating chronic inflammatory and autoimmune diseases, announced its participation in key scientific and investor conferences this March. The company will present at the 34th Annual Meeting of the Society for Virology in Hamburg, Germany, from March 4-7. Two abstracts have been selected for presentations, focusing on advancements in antiviral therapies.

Notably, Friedrich Hahn, Ph.D., from Friedrich-Alexander-Universität, will present research on dual host-targeting molecules. Alexandra Herrmann, Ph.D., from Immunic, will discuss novel DHODH inhibitors. Immunic will also participate in the Leerink Partners Global Healthcare Conference in Miami from March 10-12. CEO Daniel Vitt will engage in discussions on the firm's progress.

R. P.

Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.

Click here to consult the press release on which this article is based

See all Immunic AG news